Keywords: apotex, renews, support, cangene, program, canadian, biotechnology
Apotex renews support for Cangene's R&D program
Article | 16 February 1999
Canadian biotechnology company Cangene says that Apotex Inc has extendedits deal to support development of certain of its recombinant biopharmaceuticals. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
